Processa Pharmaceuticals Company Insiders
PCSA Stock | USD 2.37 0.10 4.41% |
Processa Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Processa Pharmaceuticals suggests that vertually all insiders are extremely bullish. Processa Pharmaceuticals employs about 15 people. The company is managed by 11 executives with a total tenure of roughly 47 years, averaging almost 4.0 years of service per executive, having 1.36 employees per reported executive.
David Young Chairman Chairman of the Board, CEO, Interim CFO, Founder |
Processa Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-02-07 | David Young | Acquired 21000 @ 2.45 | View | ||
2024-01-31 | Patrick Lin | Acquired 2500 @ 2.37 | View | ||
2024-01-30 | Justin W Yorke | Acquired 8000 @ 2.69 | View | ||
2023-06-12 | David Young | Acquired 2000 @ 16 | View | ||
2023-04-13 | David Young | Acquired 1000 @ 9.6 | View | ||
2023-04-11 | David Young | Acquired 1000 @ 10.4 | View |
Monitoring Processa Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Processa |
Processa Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Processa Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Processa will maintain a workforce of about 15 employees by April 2024.Processa Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.6926) % which means that it has lost $0.6926 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7805) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals' management efficiency ratios could be used to measure how well Processa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to -3.95. In addition to that, Return On Assets is expected to decline to -6.01. At present, Processa Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 9.7 M, whereas Total Assets are forecasted to decline to about 8.4 M.The current year's Common Stock Shares Outstanding is expected to grow to about 18.5 M, whereas Net Loss is projected to grow to (9.8 M).
Processa Pharmaceuticals Workforce Comparison
Processa Pharmaceuticals is regarded third in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 849. Processa Pharmaceuticals claims roughly 15.0 in number of employees contributing just under 2% to equities under Health Care industry.
Processa Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Processa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Processa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Processa Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2023-12-01 | 13.0 | 13 | 1 | 596,748 | 55,267 |
2023-06-01 | 3.0 | 15 | 5 | 727,595 | 100,770 |
2023-03-01 | 8.5 | 17 | 2 | 592,068 | 165,817 |
2022-12-01 | 4.5 | 9 | 2 | 138,878 | 17,114 |
2022-09-01 | 2.0 | 16 | 8 | 154,543 | 62,578 |
2022-06-01 | 6.5 | 13 | 2 | 1,375,885 | 271,788 |
2022-03-01 | 4.6667 | 14 | 3 | 162,186 | 19,569 |
2021-12-01 | 2.0 | 16 | 8 | 90,484 | 45,537 |
2021-09-01 | 4.8571 | 34 | 7 | 222,847 | 38,398 |
2021-06-01 | 1.25 | 10 | 8 | 63,762 | 911,742 |
2020-12-01 | 0.25 | 5 | 20 | 104,500 | 100,674 |
2004-06-01 | 1.0 | 1 | 1 | 1,000.00 | 0.00 |
Processa Pharmaceuticals Notable Stakeholders
A Processa Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Processa Pharmaceuticals often face trade-offs trying to please all of them. Processa Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Processa Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Wendy Guy | Founder, Chief Administrative Officer | Profile | |
Sian Bigora | Chief Development Officer, Founder | Profile | |
JD Esq | CEO Director | Profile | |
David Young | Chairman of the Board, CEO, Interim CFO, Founder | Profile | |
Patrick Lin | Founder, Chief Business & Strategy Officer, Internal Director | Profile | |
Virgil Thompson | Director | Profile | |
Justin Yorke | Director | Profile | |
James Stanker | Chief Officer | Profile | |
PharmD Bigora | CoFounder Officer | Profile | |
Robert Floyd | Chief Officer | Profile | |
PharmD Young | President, CoFounder | Profile |
About Processa Pharmaceuticals Management Performance
The success or failure of an entity such as Processa Pharmaceuticals often depends on how effective the management is. Processa Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Processa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Processa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | (4.15) | (3.95) | |
Return On Assets | (5.73) | (6.01) | |
Return On Equity | (8.44) | (8.02) |
The data published in Processa Pharmaceuticals' official financial statements usually reflect Processa Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Processa Pharmaceuticals. For example, before you start analyzing numbers published by Processa accountants, it's critical to develop an understanding of what Processa Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Processa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Processa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Processa Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Processa Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Processa Pharmaceuticals' management manipulating its earnings.
Processa Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Processa Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Processa Pharmaceuticals within its industry.Processa Pharmaceuticals Manpower Efficiency
Return on Processa Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 2M | |
Working Capital Per Employee | 492.5K | |
Working Capital Per Executive | 671.7K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Processa Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.80) | Return On Assets (0.69) | Return On Equity (1.78) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.